Sanofi agreed to a new collaboration with AI-driven biologics developer Earendil Labs that provides roughly $160 million in upfront and near‑term payments and carries potential downstream value into the multibillion range. Sanofi will lead development and global commercialization of bispecific immunology candidates discovered via Earendil’s predictive protein modeling and high‑throughput validation platform. Earendil will remain eligible for development and commercial milestones plus tiered royalties. The deal expands a continuing Sanofi–Earendil relationship and underlines Big Pharma’s continuing willingness to pay meaningful near‑term dollars for AI‑enabled biologics discovery.